论文部分内容阅读
目的观察参斛复方不同剂型治疗冠状动脉粥样硬化性心脏病的临床疗效。方法将230例冠状动脉粥样硬化性心脏病患者随机分为3组:基础治疗组30例,试验组100例和对照组100例。基础治疗组给予冠心病基础治疗,试验组予冠心病基础治疗+参斛复方中药破壁饮片(3.5 g/袋,每次1袋,每日2次,开水冲服)治疗,对照组给予冠心病基础治疗+参斛复方合剂(每次50 m L,每日2次),各组均持续治疗6个月。检测各组患者治疗前后高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、总胆固醇(TG)、同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)、血栓素(TXA2)及前列环素(PGI2)水平。结果治疗过程中脱落32例,最终完成198例。与本组治疗前比较,治疗后各组HDL、LDL、TG、Hcy及hs-CRP水平差异均无统计学意义(P>0.05),对照组和试验组TXA2水平及TXA2/PGI2比值均降低(P<0.05);与基础治疗组同期比较,治疗后对照组及试验组TXA2水平及TXA2/PGI2比值亦降低(P<0.05)。结论参斛复方不同剂型在抗血小板聚集及改善微循环具有一定作用。
Objective To observe the clinical effects of different dosage forms of Shenhu compound on coronary atherosclerotic heart disease. Methods A total of 230 patients with coronary atherosclerotic heart disease were randomly divided into three groups: 30 in the basic treatment group, 100 in the experimental group and 100 in the control group. The basic treatment group was given basic treatment of coronary heart disease. The experimental group was given basic treatment of coronary heart disease and treated with Compound Chinese Herbal Medicine broken wall (3.5 g / bag, 1 bag each time, twice a day, boiled water). The control group was given coronary heart disease Fundamentals of treatment + ginseng capsule compound (each 50 m L, 2 times a day), each group continued treatment for 6 months. The levels of high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol (TG), homocysteine (Hcy), high sensitivity C-reactive protein (TXA2) and prostacyclin (PGI2) levels. Results in the treatment of 32 cases of fall off, the final completion of 198 cases. There was no significant difference in the levels of HDL, LDL, TG, Hcy and hs-CRP between the two groups after treatment (P> 0.05), and the levels of TXA2 and TXA2 / PGI2 in the control and experimental groups decreased P <0.05). Compared with the baseline treatment group, TXA2 level and TXA2 / PGI2 ratio in the control group and the experimental group after treatment were also decreased (P <0.05). Conclusion Different dosage forms of ginseng ginseng compound may play an important role in anti-platelet aggregation and microcirculation.